Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-04EMA Authorised: Vyxeos liposomal (previously Vyxeos) (daunorubicin hydrochloride;cytarabine) — Jazz Pharmaceuticals Ireland Limited
Authorised status for Vyxeos liposomal (daunorubicin hydrochloride; cytarabine) for acute myeloid leukemia in Europe.
-
CLINICAL_TRIALS trial_result · 2026-07-23Clinical Trial Results: Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating fractionated gemtuzumab ozogamicin followed by non-engraftment donor leukocyte infusions for relapsed/re…
-
CLINICAL_TRIALS trial_result · 2026-07-14Clinical Trial Results: Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission [Phase 2]
Phase 2 trial evaluating PD-1 blockade with a dendritic cell/AML vaccine following chemotherapy-induced remission in acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2026-07-06Clinical Trial Results: First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [Phase 1, Phase 2]
First-in-human study results for SAR443579 in relapsed or refractory acute leukemias and BPDCN across Phase 1/2 cohorts; the study was termi…
-
CLINICAL_TRIALS trial_result · 2026-06-29Clinical Trial Update: Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome [Phase 3]
Phase 3 trial comparing mismatched related donor versus matched unrelated donor stem cell transplantation in pediatric and young adult patie…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-06-25Clinical Trial Update: Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy [Phase 3]
Phase 3 trial comparing azacitidine plus pevonedistat versus azacitidine in adults with acute myeloid leukemia not eligible for standard che…
-
CLINICAL_TRIALS trial_result · 2026-06-17Clinical Trial Results: A Study of E7820 in People With Bone Marrow (Myeloid) Cancers [Phase 2]
Phase 2 trial results for E7820 in myeloid bone marrow cancers have been completed with posted results.
-
CLINICAL_TRIALS trial_result · 2026-06-11Clinical Trial Results: Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia [Phase 2]
Phase 2 trial results for venetoclax and azacitidine in non-elderly adults with acute myeloid leukemia (AML) completed.
-
CLINICAL_TRIALS trial_result · 2026-06-08Clinical Trial Results: Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent [Phase 2]
Phase 2 trial evaluating recombinant EphB4-HSA with azacitidine or decitabine in relapsed/refractory MDS, CMML, or AML after hypomethylating…
-
CLINICAL_TRIALS trial_result · 2026-06-04Clinical Trial Results: A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) [Phase 3]
Phase 3 trial evaluating venetoclax plus azacitidine versus standard of care after allogeneic stem cell transplant in AML was terminated wit…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML [Phase 2]
Phase 2 global trial evaluating midostaurin combined with chemotherapy in newly diagnosed pediatric patients with FLT3-mutated acute myeloid…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia [Phase 2]
Phase 2 clinical trial evaluating the combination of decitabine, cytarabine, and daunorubicin hydrochloride for acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor [Phase 3]
Phase III study comparing ATG-thymoglobulin vs ATLG-grafalon for GVHD prophylaxis in elderly AML/MDS patients undergoing matched unrelated d…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances [Phase 1, Phase 2]
A Phase I/II clinical trial evaluating CAR.70, engineered IL-15-transduced cord blood-derived natural killer (NK) cells, in combination with…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating cytokine-induced memory-like natural killer (NK) cell adoptive therapy for relapsed acute myeloid leukem…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy [Phase 1]
A Phase 1 clinical trial is evaluating autologous peptide-induced active immunity as maintenance therapy for acute myeloid leukemia and is c…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers [Phase 2]
Phase 2 clinical trial update describing stem cell transplantation for participants with germline RUNX1-associated blood cancers; the trial …
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) [Phase 2]
Phase 2 clinical trial evaluating venetoclax with a hypomethylating agent in older or unfit adults with FLT3-mutated acute myeloid leukemia;…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome [Phase 1, Phase 2]
A phase 1/2 clinical trial is evaluating the combination of CPX-351 (liposomal cytarabine and daunorubicin) with Quizartinib for acute myelo…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies [Phase 1]
Phase 1 clinical trial evaluating autologous T cells engineered with retroviral vectors to express TCRs against patient-specific neoantigens…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT [Phase 3]
Phase 3 clinical trial evaluating mocravimod as adjunctive and maintenance therapy for adults with acute myeloid leukemia undergoing allogen…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS
This document notes an expanded access program for Galinpepimut-S (GPS) in patients with acute myeloid leukemia or myelodysplastic syndromes…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression [Phase 1, Phase 2]
AstraZeneca is evaluating AZD3632 as monotherapy or with other anticancer agents in adults with advanced hematologic malignancies associated…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial [Phase 1, Phase 2]
This entry covers ALLG AMLM26 INTERCEPT, a multi-arm Phase 1/2 precision-based platform trial at MD Anderson Cancer Center evaluating novel …
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Multiple CAR-T Cell Therapy Targeting AML [Phase 1, Phase 2]
A clinical trial update reporting Phase 1 and Phase 2 studies of multiple CAR-T cell therapies targeting acute myeloid leukemia, currently r…